Cited by 60Clinical Nutrition and GastroenterologyGut microbiota and healthLiver Disease and Transplantation

The gut-liver axis

Visschers, Ruben G.J., Luyer, Misha D., Schaap, Frank G., Olde Damink, Steven W.M., Soeters, Peter B.·2013·Current Opinion in Clinical Nutrition and Metabolic Care

Abstract

PURPOSE OF REVIEW: The liver adaptively responds to extra-intestinal and intestinal inflammation. In recent years, the role of the autonomic nervous system, intestinal failure and gut microbiota has been investigated in the development of hepatic, intestinal and extra-intestinal disease. RECENT FINDINGS: The autonomic nervous system can be stimulated via enteral fat leading to cholecystokinin release, stimulating receptors in the gut and in the brain. This promotes bowel integrity, dampening the inflammatory response to food antigens. Consensus exists that intravenously administered long-chain fatty acids can cause liver damage but randomized-controlled trials are lacking. Disruption of the enterohepatic circulation of bile salts can give rise to cholestasis and nonalcoholic fatty liver disease, which may progress to fibrosis and cirrhosis. Reduced intestinal availability of bile salts reduces stimulation of the farnesoid X receptor. This may induce hepatic bile salt overload and associated hepatotoxicity through reduced action of intestinal fibroblast growth factor 19. Evidence is put forward to suggest that the intestinal microbiota is associated with liver abnormalities. SUMMARY: Enteral lipids reduce inflammation and liver damage during stress or systemic inflammation, whereas parenteral lipid is associated with liver damage. Maintaining the enterohepatic circulation of bile salts limits hepatic cholestasis through an farnesoid X receptor feedback pathway. Changes in gut microbiota composition may induce liver disease.

Integrity signals

Registry

Crossref · 10.1097/mco.0b013e32836410a4

Cites

268 of 268 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Different types of chronic comorbidities have a final common pathway of metabolic syndrome, including fatty liver, insulin resistance, dyslipidemia, and atherosclerosis.

    “Different types of chronic comorbidities have a final common pathway of metabolic syndrome, including fatty liver, insulin resistance, dyslipidemia, and atherosclerosis.117”

    From Hypoalbuminemia: Pathogenesis and Clinical Significance (2019) · cites this paper as [117]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Visschers, R. G. J., Luyer, M. D., Schaap, F. G., Olde Damink, S. W. M., & Soeters, P. B.
Affiliations
  • Zuyderland Medisch Centrum (NL)
  • Catharina Ziekenhuis (NL)
  • Maastricht University Medical Centre (NL)
Corresponding author
Soeters, Peter B.
Venue
Current Opinion in Clinical Nutrition and Metabolic Care
Published
2013-09
Volume
16
Issue
5
Pages
576-581
ISSN
1363-1950 (ISSN-L)
OpenAlex
W1987829690
Cited by
60
References
268
Citations by year
2026: 1 · 2025: 1 · 2024: 1 · 2023: 7 · 2022: 5 · 2021: 3 · 2020: 7 · 2019: 2 · 2018: 8 · 2017: 5 · 2016: 6 · 2015: 8 · 2014: 6
FWCI
0.76
Type
journal article
Language
en
Open access
closed
Locations
  • Current Opinion in Clinical Nutrition & Metabolic Care (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Pure Amsterdam UMC (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Clinical Nutrition and Gastroenterology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
gut-liver axis, intestinal inflammation, autonomic nervous system, cholecystokinin, long-chain fatty acids, enterohepatic circulation, bile salts, cholestasis, non-alcoholic fatty liver disease, liver fibrosis, farnesoid X receptor, FGF19, gut microbiota, intestinal failure, hepatotoxicity
MeSH terms
Bile Acids and Salts, Cholecystokinin, Cholestasis, Chronic Disease, Fatty Acids, Fatty Liver, Humans, Intestinal Diseases, Liver, Fatty Acids, Omega-3, Metabolic Syndrome, Gastrointestinal Tract, Administration, Intravenous, Microbiota, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review